(Vienna, 23 December 2019) Shahrokh Shariat, Head of the Department of Urology of MedUni Vienna/Vienna General Hospital, has been awarded the Grand Central European Prize by the City of Vienna Fund for Innovative, Interdisciplinary Cancer Research.
The Grand Central European Prize is awarded for important findings in the field of innovative, interdisciplinary cancer research. It recognises the work of deserving individuals from Central Europe, who have produced globally significant scientific work in the field of cancer research.
In honour of the huge achievements of the medical schools in the "Medical City of Vienna", the City of Vienna set up the "City of Vienna Fund for Innovative, Interdisciplinary Cancer Research” in the year 2000. The purpose of this Fund is to finance research projects in all areas of innovative, interdisciplinary cancer research that promise to produce results that could advance the biological understanding, diagnosis and/or treatment of malignant diseases. Outstanding innovative achievements in the said area are recognised by the award of prizes.
About Shahrokh Shariat
Shahrokh Shariat came to Vienna from Teheran (Iran) as a child, completed his secondary education here and studied chemistry and mathematics at the Swiss Federal Polytechnic in Lausanne, before switching to a medical course at MedUni Vienna. After gaining his doctorate, Shariat went to the USA, where he completed a Research Fellowship at Baylor College of Medicine in Houston, Texas, and did his specialist training in urology at the University of Texas in Dallas. Shariat specialised in urologic oncology at the Memorial Sloan-Kettering Center in New York.
He ran the bladder cancer unit at Weill Medical College of Cornell University in New York from 2010 until 2013.
Since June 2013, he has headed up the Department of Urology of MedUni Vienna within Vienna General Hospital.
Shariat has authored more than 1,300 peer-reviewed publications and holds four patents, which were generated from his research work in the field of prostate and bladder cancer. His Scopus h-Index (Hirsch index) is 96. He was voted best urologic oncologist in New York in 2012.
He has twice been nominated one of the leading urologists in the USA. He is the only person to have been awarded both of the top prizes in urology: the EAU Crystal Matula Award 2014 and the AUA Gold Cystoscope Award 2017.
Shariat holds adjunct professorships at Cornell University in New York, the University of Texas Southwestern in Dallas, Charles University in Prague and Sechenov First Moscow State Medical University, an honorary doctorate from Carol Davila University of Medicine and Pharmacy (Romania), as well as an honorary professorship from the University of Jordan.